Community-acquired pneumonia: the annual cost to the National Health Service in the UK

The aim of this study was to estimate the direct annual healthcare costs to the UK National Health Service (NHS) of managing community-acquired pneumonia. Using a prevalence-based burden of illness approach, health service resource use and corresponding costs attributable to the management of community-acquired pneumonia during 1992/1993 in the UK were obtained from published sources and commercial databases, and supplemented by a telephone survey of general practitioners, finance directors, community nurses, receptionists and nurses in out-patient respiratory clinics, ambulance services, and consultant respiratory physicians. The study was appraised by a Peer Review Panel, representing a cross-section of experts from different locations. This study was a predefined subgroup analysis of a previous, larger study that estimated the annual cost to the NHS of treating all community-acquired lower respiratory tract infections. The analysis shows that there are 261,000 episodes of community-acquired pneumonia annually in the UK, costing 440.7 million pounds at 1992/1993 prices (32% of the annual cost for all community-acquired lower respiratory tract infections). Approximately 83,153 annual cases of community-acquired pneumonia are treated in hospital (32% of all episodes) and account for 96% of the annual cost. The average cost for managing pneumonia in the community is 100 pounds per episode, compared to 1,700-5,100 pounds when the patient is hospitalized, depending on the length of hospitalization. Hospitalization accounts for 87% of the total annual cost. In conclusion, community-acquired pneumonia in the UK incurs a direct healthcare cost of 440.7 million pounds annually at 1992/1993 prices. Developing and implementing strategies to prevent and minimize hospitalization will significantly reduce this annual cost and should be assessed in future studies.

This article has been cited by other articles:

				S. Reyes, R. Martinez, J. M. Valles, E. Cases, and R. Menendez Determinants of hospital costs in community-acquired pneumonia Eur. Respir. J., May 1, 2008; 31(5): 1061 - 1067. [Abstract] [Full Text] [PDF]

				M. Christ-Crain and B. Muller Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators Eur. Respir. J., September 1, 2007; 30(3): 556 - 573. [Abstract] [Full Text] [PDF]

				M. Valencia, J. R. Badia, M. Cavalcanti, M. Ferrer, C. Agusti, J. Angrill, E. Garcia, J. Mensa, M. S. Niederman, and A. Torres Pneumonia Severity Index Class V Patients With Community-Acquired Pneumonia: Characteristics, Outcomes, and Value of Severity Scores Chest, August 1, 2007; 132(2): 515 - 522. [Abstract] [Full Text] [PDF]

				R. Menendez, S. Reyes, R. Martinez, P. de la Cuadra, J. Manuel Valles, and J. Vallterra Economic evaluation of adherence to treatment guidelines in nonintensive care pneumonia Eur. Respir. J., April 1, 2007; 29(4): 751 - 756. [Abstract] [Full Text] [PDF]

				G. Barlow, D. Nathwani, F. Williams, S. Ogston, J. Winter, M. Jones, P. Slane, E. Myers, F. Sullivan, N. Stevens, et al. Reducing door-to-antibiotic time in community-acquired pneumonia: controlled before-and-after evaluation and cost-effectiveness analysis Thorax, January 1, 2007; 62(1): 67 - 74. [Abstract] [Full Text] [PDF]

				G. D Mills and R. Laing Severe community acquired pneumonia BMJ, December 9, 2006; 333(7580): 1181 - 1182. [Full Text] [PDF]

				J. J. Oosterheert, M. J M Bonten, M. M E Schneider, E. Buskens, J.-W. J Lammers, W. M N Hustinx, M. H H Kramer, J. M Prins, P. H T. J Slee, K. Kaasjager, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial BMJ, December 9, 2006; 333(7580): 1193 - 1193. [Abstract] [Full Text] [PDF]

				M. H. Kollef, A. Shorr, Y. P. Tabak, V. Gupta, L. Z. Liu, and R. S. Johannes Epidemiology and Outcomes of Health-care-Associated Pneumonia: Results From a Large US Database of Culture-Positive Pneumonia Chest, December 1, 2005; 128(6): 3854 - 3862. [Abstract] [Full Text] [PDF]

				E Hak, J Bont, A. Hoes, and T. Verheij Prognostic factors for serious morbidity and mortality from community-acquired lower respiratory tract infections among the elderly in primary care Fam. Pract., August 1, 2005; 22(4): 375 - 380. [Abstract] [Full Text] [PDF]

				T. J. Marrie and L. Wu Factors Influencing In-hospital Mortality in Community-Acquired Pneumonia: A Prospective Study of Patients Not Initially Admitted to the ICU Chest, April 1, 2005; 127(4): 1260 - 1270. [Abstract] [Full Text] [PDF]

				R Menendez, A Torres, R Zalacain, J Aspa, J J Martin Villasclaras, L Borderias, J M Benitez Moya, J Ruiz-Manzano, F Rodriguez de Castro, J Blanquer, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome Thorax, November 1, 2004; 59(11): 960 - 965. [Abstract] [Full Text] [PDF]

				J-B. Wasserfallen, V. Erard, A. Cometta, T. Calandra, and O. Lamy Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia Eur. Respir. J., October 1, 2004; 24(4): 644 - 648. [Abstract] [Full Text] [PDF]

				M. Bartolome, J. Almirall, J. Morera, G. Pera, V. Ortun, J. Bassa, I. Bolibar, X. Balanzo, A. Verdaguer, and the Maresme Community-Acquired Pneumonia Study Gro A population-based study of the costs of care for community-acquired pneumonia Eur. Respir. J., April 1, 2004; 23(4): 610 - 616. [Abstract] [Full Text] [PDF]

				R. Menendez, M.J. Cremades, E. Martinez-Moragon, J.J. Soler, S. Reyes, and M. Perpina Duration of length of stay in pneumonia: influence of clinical factors and hospital type Eur. Respir. J., October 1, 2003; 22(4): 643 - 648. [Abstract] [Full Text] [PDF]

				M. F. Drummond, D. L. Becker, M. Hux, J. V. M. Chancellor, I. Duprat-Lomon, R. Kubin, and P.-P. Sagnier An Economic Evaluation of Sequential IV/po Moxifloxacin Therapy Compared to IV/po Co-amoxiclav With or Without Clarithromycin in the Treatment of Community-Acquired Pneumonia Chest, August 1, 2003; 124(2): 526 - 535. [Abstract] [Full Text] [PDF]

				M. E. Singer, I. Harding, M. R. Jacobs, and D. H. Jaffe Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model J. Antimicrob. Chemother., May 1, 2003; 51(5): 1269 - 1282. [Abstract] [Full Text] [PDF]

				P.P. Espana, A. Capelastegui, J.M. Quintana, A. Soto, I. Gorordo, M. Garcia-Urbaneja, and A. Bilbao A prediction rule to identify allocation of inpatient care in community-acquired pneumonia Eur. Respir. J., April 1, 2003; 21(4): 695 - 701. [Abstract] [Full Text] [PDF]

				V. Kaplan, G. Clermont, M. F. Griffin, J. Kasal, R. S. Watson, W. T. Linde-Zwirble, and D. C. Angus Pneumonia: Still the Old Man's Friend? Arch Intern Med, February 10, 2003; 163(3): 317 - 323. [Abstract] [Full Text] [PDF]

				Y. Seppa, A. Bloigu, P. O. Honkanen, L. Miettinen, and H. Syrjala Severity Assessment of Lower Respiratory Tract Infection in Elderly Patients in Primary Care Arch Intern Med, December 10, 2001; 161(22): 2709 - 2713. [Abstract] [Full Text] [PDF]

				BTS Guidelines for the Management of Community Acquired Pneumonia in Adults Thorax, December 1, 2001; 56(90004): iv1 - 64. [Full Text] [PDF]

				R. Menendez, D. Ferrando, J.M. Valles, E. Martinez, and M. Perpina Initial risk class and length of hospital stay in community-acquired pneumonia Eur. Respir. J., July 1, 2001; 18(1): 151 - 156. [Abstract] [Full Text] [PDF]

				W S Lim, J T Macfarlane, T C J Boswell, T G Harrison, D Rose, M Leinonen, and P Saikku Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines Thorax, April 1, 2001; 56(4): 296 - 301. [Abstract] [Full Text]

				W. S. Lim, S. Gander, R. G. Finch, and J. T. Macfarlane A novel method for collecting and detecting amoxycillin in urine: a tool for testing antibiotic compliance in the community J. Antimicrob. Chemother., November 1, 2000; 46(5): 835 - 837. [Abstract] [Full Text] [PDF]

				B. Feagan Treatment and outcomes of community-acquired pneumonia at Canadian hospitals Can. Med. Assoc. J., May 1, 2000; 162(10): 1415 - 1420.

				W S Lim, S Lewis, and J T Macfarlane Severity prediction rules in community acquired pneumonia: a validation study Thorax, March 1, 2000; 55(3): 219 - 223. [Abstract] [Full Text]

				T. J. Marrie, C. Y. Lau, S. L. Wheeler, C. J. Wong, M. K. Vandervoort, B. G. Feagan, and for the CAPITAL Study Investigators A Controlled Trial of a Critical Pathway for Treatment of Community-Acquired Pneumonia JAMA, February 9, 2000; 283(6): 749 - 755. [Abstract] [Full Text] [PDF]

				W. F Holmes and M. Woodhead Issues at the interface between primary and secondary care in the management of common respiratory disease bullet 4: Providing better care for patients who may have pneumonia Thorax, October 1, 1999; 54(10): 925 - 928. [Full Text]